Form 4: Disc Medicine CFO Sells Shares Under Pre-Arranged Trading Plan

Disc Medicine's Chief Financial Officer, Jean M. Franchi, sold 2,031 shares of common stock for $59 per share on July 17, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Jean M. Franchi, Chief Financial Officer of Disc Medicine, Inc., reported the sale of 2,031 shares of the company's common stock.
• The transaction occurred on July 17, 2025, with shares sold at a price of $59 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on March 10, 2025.
• Following this transaction, Jean M. Franchi directly holds 63,499 shares of Disc Medicine common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, the execution under a Rule 10b5-1 plan suggests a pre-planned personal financial decision rather than a reaction to negative company-specific news, thus mitigating potential negative interpretations.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled sale rather than a reaction to immediate market conditions or new information, which can mitigate negative perceptions often associated with insider selling.

Negatives

• The sale of shares by a Chief Financial Officer, even under a 10b5-1 plan, represents a reduction in insider ownership, which some investors might interpret as a lack of confidence, although this is often for personal financial planning.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing reports a routine insider transaction under a pre-arranged trading plan, which is common practice for corporate executives for personal financial management. It does not provide information related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a CFO could be viewed with slight caution, but the 10b5-1 plan context generally reduces concerns about its implications for company performance. The impact is likely minimal given the pre-planned nature.

Key Dates

Keywords

Disc Medicine, IRON, Form 4, insider trading, stock sale, CFO, Jean M. Franchi, 10b5-1 plan, common stock